Biofrontera (BFRI) Net Income towards Common Stockholders (2020 - 2025)

Biofrontera's Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at $7.9 million for Q4 2025.

• On a quarterly basis, Net Income towards Common Stockholders rose 663.9% year-over-year to $7.9 million in Q4 2025; TTM through Dec 2025 was -$8.3 million, a 53.24% increase from a year earlier, with the FY2025 full-year figure at -$8.3 million, up 53.24% from the prior year.
• Net Income towards Common Stockholders climbed to $7.9 million in Q4 2025 per BFRI's latest filing, from -$6.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $7.9 million in Q4 2025 and bottomed at -$16.0 million in Q3 2021.
• The 5-year median for Net Income towards Common Stockholders is -$3.9 million (2021), against an average of -$4.2 million.
• Across the five-year window, Net Income towards Common Stockholders tumbled 7698.39% in 2021 and surged 663.9% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$14.5 million in 2021, then soared by 80.8% to -$2.8 million in 2022, then jumped by 226.61% to $3.5 million in 2023, then plunged by 139.59% to -$1.4 million in 2024, then jumped by 663.9% to $7.9 million in 2025.
• Per Business Quant, the three latest BFRI Net Income towards Common Stockholders figures stand at $7.9 million (Q4 2025), -$6.6 million (Q3 2025), and -$5.3 million (Q2 2025).